Morgan Ventures reported a net loss of ₹234.11 lakh for the first quarter ended June 30, 2026 (Q1FY27), compared to a net profit of ₹104.58 lakh in the same period last year. The Board of Directors approved the unaudited standalone financial results on August 7, 2026, alongside the reappointment of Kuldeep Kumar Dhar as Managing Director for a five-year term effective from August 14, 2026. This governance update coincides with significant financial headwinds, including rising interest expenses that exceeded total income during the quarter.

The company’s total income declined to ₹285.44 lakh in Q1FY27 from ₹552.53 lakh in Q1FY26, primarily due to a sharp drop in investment income and fair value gains. Expenses surged to ₹604.24 lakh from ₹486.14 lakh, driven largely by interest payments on loans which rose to ₹441.95 lakh from ₹275.64 lakh. Consequently, the operating loss before tax widened to ₹318.80 lakh from a profit of ₹66.39 lakh in the prior year period. The debt-equity ratio increased to 2.32 from 1.88, signaling heightened leverage risks.

Governance Updates

In addition to the financial results, the Board approved several key governance matters subject to shareholder approval at the 39th Annual General Meeting (AGM) scheduled for September 2, 2026. Kuldeep Kumar Dhar, who brings over five decades of experience in business development and management, was reappointed as Managing Director for a term ending August 13, 2031. The Board also recommended the reappointment of Sanjiv Bansal as an Independent Director for a second consecutive term of five years, commencing June 17, 2026.

The AGM will also seek approval for material related-party transactions with Morgan Securities & Credits Private Limited and Peacock Chemicals Private Limited. These transactions, involving loans, advances, and services, are capped at ₹200 crore each for the financial year 2026-27. The proposed values represent 652% of the company’s annual consolidated turnover for FY25-26, necessitating shareholder consent under Regulation 23 of the SEBI Listing Regulations.

Financial Performance Analysis

The deterioration in profitability is primarily attributable to the surge in interest costs, which consumed more than half of the total income in Q1FY27. Investment income fell sharply to ₹75.74 lakh from ₹278.42 lakh, while net gains from fair value changes of investments dropped to ₹209.70 lakh from ₹274.11 lakh. Management expenses associated with IIFL decreased to ₹155.00 lakh from ₹195.45 lakh, but this reduction was insufficient to offset the higher interest burden.

What the Numbers Show

The widening loss and increasing debt-equity ratio highlight the pressure on Morgan Ventures’ balance sheet. With interest payments exceeding operational and investment income, the company faces immediate challenges in maintaining liquidity without relying on related-party funding. The approval of large-scale related-party transactions up to ₹200 crore with group entities suggests a strategic reliance on internal capital markets to sustain operations. Investors should monitor the outcome of the ongoing legal dispute regarding land assets valued at ₹20.02 crore, which remains under litigation with the Maharashtra Industrial Development Corporation (MIDC). The resolution of this matter could impact future asset valuations and potential collateral availability.

Morgan Ventures Limited has approved the re-appointment of Dr. Sanjiv Bansal as an Independent Director for a second term of five years, effective June 17, 2026. The decision, taken by the Board of Directors on May 29, 2026, is subject to the approval of the company's shareholders. This move ensures continuity in the company's governance structure as Dr. Bansal completes his first term.

The re-appointment follows the recommendation of the Nomination and Remuneration Committee. Dr. Bansal's new term will commence on June 17, 2026, and conclude on June 17, 2031. He will not be liable to retire by rotation during this period. The company disclosed these details in a filing submitted to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dr. Sanjiv Bansal is a physician by profession, having completed his education at the University of Mysore. He brings extensive experience in diagnosing and managing a wide range of medical conditions. Beyond his medical practice, he owns Bansal Hospitals in Delhi and possesses significant management experience through directorships in various companies.

The disclosure confirms that Dr. Bansal is not related to any other director on the Board of Morgan Ventures Limited. Furthermore, he is not debarred from holding the office of director by any order of the Securities and Exchange Board of India or any other regulatory authority, as required under relevant circulars.

Details of Re-appointment